abstract |
The present invention provides a novel ICOS agonist antibody as an immunomodulator in cancer, infectious diseases and / or sepsis. An agonistic antibody against human ICOS comprising a specific sequence that activates T cells, stimulates T cell proliferation and / or induces cytokine production when placed in contact with T cells. An ICOS antibody or antigen-binding portion thereof that can, but does not induce complement, ADCC or CDC in vivo, and a method of treating cancer, infectious disease and / or sepsis with said ICOS antibody or antigen-binding portion thereof. [Selection figure] None |